SCHEDULE: BlackRock Discloses 6.5% Passive Stake in aTYR Pharma Inc.
Ownership Disclosure
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 6.5% in aTYR Pharma Inc.'s common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 5,763,606 shares of aTYR Pharma Inc. common stock.
- This ownership represents 6.5% of the total outstanding common stock of aTYR Pharma Inc.
- BlackRock holds sole voting power over 5,666,039 shares and sole dispositive power over 5,763,606 shares.
- The filing is a Schedule 13G under Rule 13d-1(b), indicating a passive investment not intended to change or influence control of the issuer.
- BlackRock, Inc. filed as a parent holding company, with certain subsidiaries identified as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing disclosing a passive ownership stake. It provides factual information without indicating positive or negative operational performance or strategic shifts for the issuer.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, revoking a previous one dated April 30, 2023, and appointing new attorneys-in-fact for compliance with ownership reporting requirements. | 2025-01-21 | Streamlines BlackRock's internal process for SEC and other regulatory filings related to ownership disclosures. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in aTYR Pharma Inc.
- Investment Professionals: Confirms BlackRock's continued or new passive investment in aTYR Pharma Inc., which may be noted in their analysis.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which required the filing of this Schedule 13G, indicating the reporting period end for the ownership stake. |
| 2025-07-17 | Date the Schedule 13G was signed and filed by BlackRock, Inc. |
Keywords
BlackRock, aTYR Pharma Inc, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.